

Media (UK):

Michael Hindmarsh

Exact@bcw-global.com

Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium® Supporting Optimization and Individualization of Therapy for Breast Cancer Patients

- *Irish National analysis of the clinical and economic impact of the Oncotype DX® test for patients with node positive breast cancer (NI)*
- *Additional analysis of the Holt UK decision impact study: A comparison of chemotherapy recommendations by NPI, Predict, and Oncotype DX® testing in women with early node positive breast cancer*
- *Updated TAILORx follow-up data showing the integration of clinico-pathologic criteria and Recurrence Score® results to refine distant recurrence risk estimates.*
- *New concordance analysis supporting the generation of Oncotype DX® results from core needle biopsy to personalize treatment decisions.*
- *ADAPTCycle trial data, using Oncotype DX® results and endocrine response to stratify patients, may expand the number of breast cancer patients able to forgo chemotherapy post-surgery; chosen as late-breaking abstract.*

London, December 4, 2023 -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present new data and study results across its Precision Oncology and hereditary cancer platforms at the 2023 annual San Antonio Breast Cancer Symposium (SABCS®).

“Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes,” said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. “Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world’s most prestigious, breast cancer-focused organizations.”

Data presentations including those from Exact Sciences at SABCS 2023:

1. **Title:** Impact of age and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Results from the multicenter ADAPTCycle trial
Chosen as Late Breaking Abstract at SABCS

Data embargoed until: 7:15 am CT on Friday, December 8

Presentation ID: LBO1-05: Friday December 8, 12-12:45pm CT

- Title:** Concordance Study of Oncotype DX Breast Recurrence Score Results from Paired Breast Cancer Core Needle Biopsies and Surgical Excision Specimens

Summary: Comparison of Oncotype DX Recurrence Score results for paired core needle biopsy and surgical samples of the same tumor without intervening systemic therapy, which found high concordance between the two.

Presentation ID: PO4-08-09: Thursday December 7, 5-7pm CT

- Title:** Update of RSCLin tool with extended TAILORx follow-up and development and validation of a new tool for risk of late distant recurrence

Summary. Update of the TAILORx findings with longer follow-up and resulting refinements to the RSCLin tool for estimating 10-year risk of distant recurrence in HR+HER2- early breast cancer. A new tool specifically to estimate late (5-10 year) distant recurrence risk is also presented.

Presentation ID: PO1-02-02: Poster Session 1, Wednesday December 6, 12–2pm CT

- Title:** A comparison of chemotherapy recommendations by NPI, Predict, and Oncotype DX testing in UK women with early node positive breast cancer

Summary. Comparison of the Oncotype DX Recurrence Score test, the Nottingham Prognostic Index, and the Predict Breast Cancer tool in risk stratification and association with chemotherapy recommendations in HR+HER2- node-positive early breast cancer. Of the three, the Oncotype test was the most strongly associated with chemotherapy recommendation.

Presentation ID: PO1-14-05: Wednesday December 6, 12–2pm CT

- Title:** Irish National Analysis of the Clinical and Economic impact of 21-gene Oncotype DX® testing in Early-Stage, 1-3 lymph node positive, Hormone Receptor positive (HR+), HER2-Negative (HER2-), Breast Cancer (BC)

Summary: An analysis of the impact of Oncotype DX® testing in a N1 (disease with 1-3 positive LN) breast cancer population from 2 Irish cancer centers identified a 55% reduction in chemotherapy use with savings of over €1 million. The objectives of this study were to examine the clinical and economic impact of Oncotype DX testing on treatment decisions in N1 patients at a national level with a larger patient population, and to examine changes in the ordering of Oncotype DX tests pre and post RxPONDER data. This study extended the analysis to 5 Irish cancer centers.

Presentation ID: PO5-02-04: Friday December 8, 12-2pm CT

- 6. Title:** Real world application of a 21-gene recurrence score in a Swiss single center breast cancer population. A comparative analysis of treatment administration before and after TAILORx

Summary: A comparison of chemotherapy recommendations and use before and after TAILORx. There were some differences in treatment recommendations after TAILORx that included increased recommendation for addition of chemotherapy to endocrine therapy, specifically among younger women, but there were no significant changes in chemotherapy administration.

Presentation ID: Poster Number: P1-14-02: Wednesday December 6, 12-2pm CT

- 7. Title:** Comparison of the cost-effectiveness of multigene assays for HR+/HER2- node-negative early-stage breast cancer in the US

Summary: Compares the cost-effectiveness of using different genomic assays for treatment decisions in HR+HER2- early breast cancer (Oncotype DX, MammaPrint, EndoPredict, and Prosigna ROR) relative to that of using clinical-pathological features alone in the U.S. The modeling found that all were cost-effective as additions to clinical-pathological features, with the Oncotype DX test providing the greatest cost savings among the four.

Presentation ID: PO1-01-10: Poster Session 1, Wednesday December 6, 12-2pm CT

About Exact Sciences Corp.

A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard[®] and Oncotype[®] tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X (formerly known as Twitter) @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.

NOTE: Oncotype, Oncotype DX, Oncotype DX Breast Recurrence Score and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc., a wholly-owned subsidiary of Exact Sciences Corporation. Exact Sciences and Cologuard are trademarks or registered trademarks of Exact Sciences Corporation. All other trademarks and service marks are the property of their respective owners.

Forward-Looking Statements

This news release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated. You should not place undue reliance on forward-looking statements. Risks and uncertainties that may affect our forward-looking statements are described in the Risk Factors sections of our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-

looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.